- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 19, 2019
Highlights
- Market Cap
- $21.42M
- Enterprise Value
- $92.97M
- EPS (TTM)
- -$3.06
- Total Revenue (TTM)
- $40.58M
- Gross Profit (TTM)
- $22.42M
- EBITDA (TTM)
- -$63.56M
- Year Range
- $0.00 - $0.06
- ROA (TTM)
- -75.14%
- ROE (TTM)
- 211.88%
- Avg. Volume (1M)
- 125K
- Avg. Volume Value (1M)
- $236.50
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CELUW Performance Chart
Celularity Inc (CELUW) is down 88.3% since the beginning of the year. At $0 per share, CELUW is trading 96.8% below its 52-week high of $0. Investors who bought $1,000 worth of CELUW shares 5 years ago would now be looking at an investment worth $1.
Loading charts...
Compare this symbol against anything
Returns By Period
Celularity Inc (CELUW) has returned -88.31% so far this year and -96.20% over the past 12 months.
Celularity Inc
- 1D
- 0.00%
- 1M
- -51.28%
- 6M
- -79.57%
- YTD
- -88.31%
- 1Y
- -96.20%
- 3Y*
- -67.13%
- 5Y*
- -74.77%
- 10Y*
- —
- ALL TIME*
- -55.99%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
CELUW Monthly Returns History
Based on dividend-adjusted daily data since Jul 19, 2019, CELUW's average daily return is +1.31%, while the average monthly return is +5.37%. At this rate, an investment would double in approximately 1.1 years.
Historically, 41% of months were positive and 59% were negative. The best month was Dec 2023 with a return of +545.2%, while the worst month was Dec 2022 at -73.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, CELUW closed higher 37% of trading days. The best single day was Jul 17, 2026 with a return of +533.3%, while the worst single day was Jul 15, 2026 at -72.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -42.77% | -24.73% | 41.43% | -9.09% | -28.89% | -29.69% | -57.78% | -88.31% | |||||
| 2025 | 288.33% | -41.34% | -2.44% | -0.25% | 50.38% | -26.17% | 35.44% | 0.00% | -41.50% | -29.06% | -1.20% | -33.94% | -9.72% |
| 2024 | -20.75% | 18.29% | 9.60% | -14.84% | -42.86% | -24.00% | 20.39% | 8.74% | -49.25% | 77.23% | 11.51% | -9.82% | -55.00% |
| 2023 | 36.36% | -14.89% | -21.67% | 3.50% | 1.29% | -8.90% | -15.01% | -59.34% | -23.23% | 25.32% | -67.45% | 545.16% | -39.39% |
| 2022 | -43.02% | 65.33% | 69.11% | 14.60% | -46.45% | -31.31% | -18.96% | -8.12% | -9.91% | 2.48% | -37.03% | -73.60% | -92.33% |
| 2021 | -56.94% | 25.00% | -29.03% | -1.82% | 20.37% | 4.62% | 7.35% | -0.68% | -20.69% | -11.30% | -1.96% | -14.00% | -70.14% |
Benchmark Metrics
Celularity Inc has an annualized alpha of 2442.42%, beta of 0.22, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since July 19, 2019.
- This stock participated in 251.06% of S&P 500 Index downside but only 5.18% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.22 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 2,442.42%
- Beta
- 0.22
- R²
- 0.00
- Upside Capture
- 5.18%
- Downside Capture
- 251.06%
Return for Risk
Risk / Return Rank
CELUW ranks 44 for risk / return — above 44% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Celularity Inc (CELUW) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CELUW | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.58 | ||
| Sortino ratioReturn per unit of downside risk | +0.30 | ||
| Omega ratioGain probability vs. loss probability | 1.32 | 1.25 | +0.06 |
| Calmar ratioReturn relative to maximum drawdown | -0.97 | 2.00 | -2.97 |
| Martin ratioReturn relative to average drawdown | -1.35 | 8.49 | -9.84 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Celularity Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Celularity Inc was 99.99%, occurring on Jul 15, 2026. The portfolio has not yet recovered.
The current Celularity Inc drawdown is 99.94%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.99%Jul 2026 | 5y 6mo | — | 5y 6moJan 2021 - now | — |
-50.75%Apr 2020 | 1mo 10d | 2mo 14d | 3mo 24dMar 2020 - Jun 2020 | COVID crash2020 |
-32.53%Nov 2020 | 1mo 25d | 1mo 7d | 3mo 2dSep 2020 - Dec 2020 | — |
-25.17%Dec 2020 | 3d | 10d | 13dDec 2020 - Dec 2020 | — |
-25.00%Jul 2019 | 6d | 2d | 8dJul 2019 - Jul 2019 | — |
Drawdown Indicators
| CELUW | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.99% | -56.78% | -43.21% |
Max Drawdown (1Y)Largest decline over 1 year | -99.50% | -9.10% | -90.40% |
Max Drawdown (3Y)Largest decline over 3 years | -99.75% | -18.90% | -80.85% |
Max Drawdown (5Y)Largest decline over 5 years | -99.98% | -25.43% | -74.55% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.94% | -1.58% | -98.36% |
Average DrawdownAverage peak-to-trough decline | -76.54% | -10.70% | -65.84% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 71.40% | 2.14% | +69.26% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Celularity Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Celularity Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CELUW relative to other companies in the Biotechnology industry. Currently, CELUW has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CELUW
Add Celularity Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CELUW